5488-36-8

Basic information

• Product Name: 4,4-dimethylisoquinoline-1,3(2H,4H)-dione
• CAS NO: 5488-36-8
• Molecular Formula: C₁₁H₁₁NO₂
• Molecular Weight: 189.2105
• Mol File: 5488-36-8.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 357.8°C at 760 mmHg
• Flash Point: 158.1°C
• Density: 1.155g/cm³
• Vapor Pressure: 2.65E-05mmHg at 25°C
• Refractive Index: 1.539
• CAS DataBase Reference: 4,4-dimethylisoquinoline-1,3(2H,4H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 4,4-dimethylisoquinoline-1,3(2H,4H)-dione(5488-36-8)
• EPA Substance Registry System: 4,4-dimethylisoquinoline-1,3(2H,4H)-dione(5488-36-8)

Safety Data

• Hazardous Substances Data: 5488-36-8(Hazardous Substances Data)

Upstream product

• 40484-15-9 α,α-dimethylhomophthalic acid 
• 2317-22-8 2,6-dicyanotoluene 
• 25316-59-0 benzyl tri-n-butylammonium bromide 
• 99911-10-1 2-(2-cyanopropan-2-yl)benzonitrile 
• 74-88-4 methyl iodide 
• 4456-77-3 4H-isoquinolin-1,3-dione 

Downstream Products

• 788100-09-4 1-[4,4-Dimethyl-1,3-dioxo(2H,4H)-isoquinolin-2-yl]-3-[4-phenyl-piperazin-1-yl]-propane 
• 100510-65-4 6-Amino-3,3-dimethylindolin-2-one 
• 100510-64-3 1,3-Dihydro-3,3-dimethyl-6-nitro-2H-indol-2-one 
• 1026910-04-2 1-(8-amino-4,4-dimethyl-1,3-dioxo-1,2,3,4-tetrahydro-isoquinolin-7-yl)-3-(2,3,5,6-tetrachloro-phenyl)-thiourea 
• 1026270-01-8 1-(8-amino-4,4-dimethyl-1,3-dioxo-1,2,3,4-tetrahydro-isoquinolin-7-yl)-3-(2,4,6-trichloro-phenyl)-thiourea 
• 1027961-53-0 1-(8-amino-4,4-dimethyl-1,3-dioxo-1,2,3,4-tetrahydro-isoquinolin-7-yl)-3-(2,4-dichloro-phenyl)-thiourea 
• 1027266-81-4 1-(8-amino-4,4-dimethyl-1,3-dioxo-1,2,3,4-tetrahydro-isoquinolin-7-yl)-3-(2,6-difluoro-phenyl)-thiourea 
• 1027556-48-4 1-(8-amino-4,4-dimethyl-1,3-dioxo-1,2,3,4-tetrahydro-isoquinolin-7-yl)-3-(2-chloro-6-methyl-phenyl)-thiourea 
• 333458-24-5 1-(8-amino-4,4-dimethyl-1,3-dioxo-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-(2,6-dichlorophenyl)thiourea 

Relevant articles and documents

1,3,4-OXADIAZOLE HOMOPHTHALIMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to novel compounds having a histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, a medicinal use thereof, and a method for preparing the same. The novel compounds according to the present invention, stereoisomers thereof or pharmaceutically acceptable salts thereof have the histone deacetylase 6 (HDAC6) inhibitory activity, and are effective in preventing or treating HDAC6-related diseases, comprising infectious diseases; neoplasm; endocrinopathy; nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; eye and ocular adnexal diseases; circulatory diseases; respiratory diseases; digestive diseases; skin and subcutaneous tissue diseases; musculoskeletal system and connective tissue diseases; and teratosis or deformities, or chromosomal aberration.

Intramolecular photoreactions of thiohomophthalimides with an alkenyl group in their N-side chain. Regioselective synthesis of heterocycle-fused isoquinoline derivatives through [2+2] photocycloaddition

Upon irradiation, thiohomophthalimides with an alkenyl group in their N-side chain or at the benzylic position give tricyclic isoquinoline derivatives through regioselective intramolecular [2+2] cycloaddition or Norrish type II reaction, respectively, in

Discovery of 2-phenylamino-imidazo[4,5-h]isoquinolin-9-ones: A new class of inhibitors of lck kinase

An imidazo[4,5-h]isoquinolin-7,9-dione (1) was identified as an adenosine 5′-triphosphate competitive inhibitor of lck by high throughput screening. Initial structure-activity relationship studies identified the dichlorophenyl ring and the imide NH as important pharmacophores. A binding model was constructed to understand how 1 binds to a related kinase, hck. These results suggested that removing the gem-dimethyl group and flattening the ring would enhance activity. This was realized by converting 1 to the imidazo[4,5-h]isoquinolin-9-one (20), resulting in an 18-fold improvement in potency against lck and a 50-fold increase in potency in a cellular assay.